Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGM BGM Group	$13.00 +0.7%	$12.49	$5.26 ▼ $17.17	$1.26B	1.38	33,296 shs	106,626 shs
MESO Mesoblast	$10.55 +1.0%	$11.31	$5.78 ▼ $22.00	$1.35B	2.41	274,578 shs	158,245 shs
TVTX Travere Therapeutics	$14.94 -2.0%	$16.90	$7.67 ▼ $25.29	$1.33B	0.75	1.60 million shs	824,666 shs
YSB YS Biopharma		$1.25	$0.35 ▼ $1.78	$344.32M	0.51	172,401 shs	63,510 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGM BGM Group	-1.60%	+2.06%	-11.94%	+11.01%	+1,290,999,900.00%
MESO Mesoblast	+2.85%	-11.21%	-3.69%	-24.55%	+54.13%
TVTX Travere Therapeutics	+5.18%	+8.16%	-3.79%	-26.70%	+95.64%
YSB YS Biopharma	0.00%	0.00%	0.00%	0.00%	+270.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BGM BGM Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	2.7151 of 5 stars	3.5	3.0	0.0	0.0	3.2	0.8	0.6
TVTX Travere Therapeutics	2.3858 of 5 stars	4.4	1.0	0.0	0.0	1.2	0.8	0.6
YSB YS Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGM BGM Group	0.00	N/A	N/A	N/A
MESO Mesoblast	3.00	Buy	$18.00	71.41% Upside
TVTX Travere Therapeutics	2.87	Moderate Buy	$32.14	113.19% Upside
YSB YS Biopharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest YSB, MESO, TVTX, and BGM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	TVTX Travere Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$30.00
6/11/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$35.00 ➝ $32.00
5/16/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/16/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $30.00
5/2/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $30.00
5/2/2025	TVTX Travere Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$22.00 ➝ $23.00
4/23/2025	TVTX Travere Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
4/14/2025	TVTX Travere Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$47.00 ➝ $47.00
4/11/2025	TVTX Travere Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
4/10/2025	TVTX Travere Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $47.00
3/31/2025	MESO Mesoblast	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGM BGM Group	$25.10M	51.42	N/A	N/A	$7.34 per share	1.81
MESO Mesoblast	$5.90M	227.43	N/A	N/A	$4.21 per share	2.49
TVTX Travere Therapeutics	$233.18M	5.74	N/A	N/A	$0.76 per share	19.84
YSB YS Biopharma	$560.76M	0.00	N/A	N/A	$1.14 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGM BGM Group	-$1.44M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
TVTX Travere Therapeutics	-$321.55M	-$2.81	N/A	N/A	N/A	-82.88%	-1,179.73%	-41.10%	7/30/2025 (Estimated)
YSB YS Biopharma	-$21.17M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest YSB, MESO, TVTX, and BGM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/1/2025	Q1 2025	TVTX Travere Therapeutics	-$0.55	-$0.47	+$0.08	-$0.47	$77.44 million	$81.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGM BGM Group	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A
YSB YS Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGM BGM Group	N/A	3.39	2.82
MESO Mesoblast	0.22	0.96	0.63
TVTX Travere Therapeutics	9.46	2.05	2.03
YSB YS Biopharma	0.26	0.94	0.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BGM BGM Group	N/A
MESO Mesoblast	1.43%
TVTX Travere Therapeutics	N/A
YSB YS Biopharma	52.64%

Insider Ownership

Company	Insider Ownership
BGM BGM Group	58.66%
MESO Mesoblast	18.80%
TVTX Travere Therapeutics	4.06%
YSB YS Biopharma	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BGM BGM Group	298	97.22 million	40.19 million	N/A
MESO Mesoblast	80	127.78 million	103.76 million	Optionable
TVTX Travere Therapeutics	460	88.81 million	85.20 million	Optionable
YSB YS Biopharma	773	93.06 million	N/A	Not Optionable

YSB, MESO, TVTX, and BGM Headlines

Recent News About These Companies

YS Life

October 25, 2024 | yourstory.comY

LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation

October 3, 2024 | finanznachrichten.de

LakeShore changes CEO with new executive appointments

September 5, 2024 | thepharmaletter.comT

LakeShore Biopharma Co Ltd Ordinary Shares LSB

August 17, 2024 | morningstar.comM

LSB LakeShore Biopharma Co., Ltd

July 20, 2024 | seekingalpha.com

Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Quotes, Forecast and News Summary

July 19, 2024 | benzinga.com

YS Biopharma Co., Ltd.: YS Biopharma Announces Name Change to LakeShore Biopharma

May 24, 2024 | finanznachrichten.de

YS Biopharma Announces Name Change to LakeShore Biopharma

May 24, 2024 | prnewswire.com

YS Biopharma Co., Ltd.: YS Biopharma Announces Results of Extraordinary General Meeting

May 22, 2024 | finanznachrichten.de

YS Biopharma Announces Results of Extraordinary General Meeting

May 21, 2024 | prnewswire.com

YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer

May 7, 2024 | prnewswire.com

With 80% ownership, YS Biopharma Co., Ltd. (NASDAQ:YS) insiders have a lot riding on the company's future

May 7, 2024 | finance.yahoo.com

YS Biopharma Co., Ltd.: YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

April 29, 2024 | finanznachrichten.de

YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

April 29, 2024 | prnewswire.com

YS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Call Transcript

April 22, 2024 | finance.yahoo.com

YS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

April 19, 2024 | finanznachrichten.de

YS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

April 19, 2024 | finanznachrichten.de

YS Stock Earnings: YS Biopharma Co Misses EPS, Beats Revenue for Q3 2024

April 19, 2024 | markets.businessinsider.com

YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

April 19, 2024 | prnewswire.com

YS Biopharma Co., Ltd.: YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

April 18, 2024 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

YSB, MESO, TVTX, and BGM Company Descriptions

BGM Group NASDAQ:BGM

$13.00 +0.09 (+0.70%)

Closing price 04:00 PM Eastern

Extended Trading

$13.00 +0.01 (+0.04%)

As of 04:54 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Mesoblast NASDAQ:MESO

$10.55 +0.10 (+0.96%)

Closing price 04:00 PM Eastern

Extended Trading

$10.54 -0.02 (-0.14%)

As of 04:04 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Travere Therapeutics NASDAQ:TVTX

$14.94 -0.30 (-1.97%)

Closing price 04:00 PM Eastern

Extended Trading

$14.94 +0.01 (+0.03%)

As of 06:19 PM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

YS Biopharma NASDAQ:YSB

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time